Highest-materiality recent filing
Thermo Fisher Q1 revenue $11.01B (+6% YoY); adjusted EPS $5.44 (+6%)
Q1 revenue $11.01B, up 6% YoY; organic revenue growth 1%.
Thermo Fisher issues $3.8B in senior notes to partially fund Clario acquisition
Issued four tranches: $1B 4.215% Notes due 2031, $750M 4.550% due 2033, $1.3B 4.902% due 2036, $750M 5.546% due 2046.
Thermo Fisher Q4 rev $12.21B (+7%), adj EPS $6.57 (+8%); FY rev $44.56B (+4%)
Q4 GAAP diluted EPS $5.21 (+9%); adj EPS $6.57 (+8%); GAAP operating margin 18.5%.
Thermo Fisher EVP/COO Lagarde and EVP Lowery to depart; Pettiti promoted to President and COO
Michel Lagarde, EVP & COO, leaves March 31, 2026; Frederick Lowery, EVP, leaves Feb 28, 2026.
Thermo Fisher to acquire Clario Holdings for $8.875B; deal expected to close mid-2026
$8.875B cash at closing; additional $125M deferred and up to $400M contingent consideration.
Thermo Fisher Q3 revenue $11.12B (+5%); adjusted EPS $5.79 (+10%)
Revenue $11.12B, +5% reported and +3% organic; GAAP EPS $4.27 vs $4.25 YoY.
Thermo Fisher Q2: rev +3% to $10.85B, GAAP EPS $4.28 (+6%), adj EPS $5.36
Q2 revenue $10.85B (+3% YoY; organic 2%); GAAP diluted EPS $4.28, up 6% from $4.04.
Thermo Fisher CFO Stephen Williamson to retire March 2026; James Meyer named successor
CFO Stephen Williamson will retire effective March 31, 2026.
Thermo Fisher grants CEO Casper $60M performance RSU award with TSR-based vesting through 2030
Target award of 141,538 shares (~$60M) to CEO Marc Casper; cliff vesting May 21, 2030 contingent on TSR vs S&P 500.
Thermo Fisher Q1 GAAP EPS $3.98 (+15%), revenue $10.36B; agrees to acquire Solventum biz for $4.1B
Q1 revenue $10.36B (+0.2% YoY); organic growth 1%; GAAP diluted EPS $3.98 (+15%).
Thermo Fisher to acquire Solventum's purification and filtration business for $4.1B
Deal value approximately $4.1 billion in cash.
Thermo Fisher Q4 revenue $11.40B (+5%), adj. EPS $6.10 (+8%)
Q4 GAAP diluted EPS $4.78 (+14% YoY); adjusted EPS $6.10 (+8% YoY).
Thermo Fisher Q3 revenue flat at $10.60B; adjusted EPS $5.28; raises FY adjusted EPS guidance
Revenue $10.60B, essentially flat versus $10.57B in Q3 2023; organic revenue also flat.
Thermo Fisher Q2 GAAP EPS $4.04 (+15%), Adj. EPS $5.37 (+4%), raises FY 2024 guidance
Revenue $10.54B, down 1% YoY; organic revenue -1%, core organic revenue flat.
Thermo Fisher Q1 rev $10.34B (-3%), GAAP EPS $3.46 (+4%), raises FY guidance
GAAP diluted EPS $3.46 vs $3.32 YoY; adjusted EPS $5.11 vs $5.03 (+2%).
Q4 revenue $10.89B (-5% YoY), adjusted EPS $5.67 (+5%); guides 2024 revenue $42.1-43.3B
Q4 GAAP EPS $4.20 (+5% YoY); adjusted EPS $5.67 (+5%); GAAP operating margin 17.0% vs 16.3%.
Thermo Fisher Q3 revenue $10.57B (-1% YoY); GAAP EPS $4.42 (+17%); acquires Olink for ~$3.1B
Revenue $10.57B, down 1% YoY; core organic revenue grew 1%; COVID testing revenue $0.05B.
Thermo Fisher to acquire Olink for $26/share, ~$3.1B total
Cash tender offer at $26/ADS, ~74% premium to Oct 16 close; transaction values Olink at ~$3.1B including ~$143M net cash.
Thermo Fisher issues $2.95B senior notes, redeems $1B floating-rate notes
Issued $600M 4.953% notes due 2026, $750M 4.977% notes due 2030, $1B 5.086% notes due 2033, $600M 5.404% notes due 2043.
Thermo Fisher Q2 revenue $10.69B (-3% YoY), GAAP EPS $3.51, cuts FY guidance
Q2 revenue $10.69B, down 3% YoY; core organic growth +2%; COVID testing revenue $0.08B.
Thermo Fisher Q1 revenue $10.71B (-9% YoY); GAAP EPS $3.32, adjusted EPS $5.03
Revenue $10.71B, down 9% YoY; core organic growth 6%; COVID testing revenue $0.14B.
Thermo Fisher Q4 revenue $11.45B (+7% YoY), adjusted EPS $5.40; FY2023 guidance: rev $45.3B
Q4 revenue $11.45B (+7% YoY); GAAP EPS $4.01 (vs $4.17), adjusted EPS $5.40 (vs $6.54).
Thermo Fisher Q3 revenue $10.68B, GAAP EPS $3.79, adjusted EPS $5.08
Revenue grew 14% to $10.68B; core organic revenue growth 14%.
Thermo Fisher Scientific issues ¥110 billion of senior notes in six tranches
Issued ¥22.3B in 0.853% notes due 2025, ¥28.9B in 1.054% notes due 2027, ¥4.7B in 1.279% notes due 2029.
Thermo Fisher Q2 revenue $10.97B (+18% YoY); GAAP EPS $4.22, adjusted EPS $5.51
Revenue $10.97B (+18% YoY); core organic growth 13%; COVID testing revenue $0.63B.
Thermo Fisher Q1 revenue $11.82B (+19%), adjusted EPS $7.25; raises dividend 15%
GAAP EPS $5.61 vs $5.88 last year; adjusted EPS $7.25 vs $7.21.
Thermo Fisher Q4 revenue $10.70B, adj EPS $6.54; full-year rev up 22% to $39.21B
Q4 GAAP diluted EPS $4.17 (vs $6.24); adjusted EPS $6.54 (vs $7.09); COVID-19 response rev $2.45B.
Thermo Fisher redeems $1.2B 2026 and $750M 2027 notes for ~$1.95B
Redeems $1.2B of 2.95% Senior Notes due 2026 and $750M of 3.2% Senior Notes due 2027.
Thermo Fisher completes $17.4B acquisition of clinical research firm PPD, Inc.
Total consideration $17.4 billion; PPD common stock ceased trading on Nasdaq.
increased its size to twelve members and elected Karen S. Lynch as a director of the Company, effective February 19, 2025, for a term expiring at the Company’s 2025 annual meeting.
elected Jennifer “Jenny” Johnson, president and chief executive officer of Franklin Resources, Inc., as a director of the Company, effective July 13, 2023
On February 23, 2022, the Board of Directors of Thermo Fisher Scientific Inc. (the “Company”) increased the size of its board to thirteen members and elected Ruby R. Chandy as a director of the Company for a term expiring at the Company’s 2022 annual meeting, both effective as of March 1, 2022.
Also on February 23, 2022, Thomas J. Lynch, who has served as a director of the Company since 2009, and as Lead Director since 2020, advised the Board that he plans to retire from the Board when his current term as a director expires at the 2022 annual meeting.
Mark Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific Inc. (the “Company”), notified the Company of his decision to retire effective March 18, 2022
the Board of Directors of the Company appointed Gianluca Pettiti, currently Senior Vice President and President of the Company’s Specialty Diagnostics business, Executive Vice President, effective December 27, 2021.
Syed Jafry, Senior Vice President, Regions, notified the Company of his decision to retire effective March 31, 2022.
the Board of Directors of the Company appointed Michel Lagarde, currently Executive Vice President, Executive Vice President and Chief Operating Officer, effective January 1, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings